Supernus Pharmaceuticals Inc (NASDAQ:SUPN) VP Padmanabh P. Bhatt sold 20,000 shares of the business’s stock in a transaction dated Monday, January 22nd. The stock was sold at an average price of $48.04, for a total value of $960,800.00. Following the transaction, the vice president now directly owns 32,500 shares of the company’s stock, valued at approximately $1,561,300. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.
Shares of Supernus Pharmaceuticals Inc (NASDAQ SUPN) traded down $2.65 on Monday, reaching $44.25. The company had a trading volume of 2,071,337 shares, compared to its average volume of 841,800. Supernus Pharmaceuticals Inc has a 1 year low of $23.40 and a 1 year high of $50.04. The company has a market capitalization of $2,260.00, a price-to-earnings ratio of 40.23 and a beta of 1.17.
Supernus Pharmaceuticals (NASDAQ:SUPN) last released its quarterly earnings data on Monday, November 6th. The specialty pharmaceutical company reported $0.29 earnings per share for the quarter, beating the consensus estimate of $0.27 by $0.02. Supernus Pharmaceuticals had a return on equity of 26.37% and a net margin of 20.98%. The company had revenue of $80.40 million for the quarter, compared to analyst estimates of $78.74 million. The firm’s quarterly revenue was up 41.5% on a year-over-year basis. equities analysts expect that Supernus Pharmaceuticals Inc will post 1.07 earnings per share for the current year.
Several equities analysts recently issued reports on SUPN shares. Piper Jaffray Companies restated a “hold” rating and set a $41.00 price target on shares of Supernus Pharmaceuticals in a research note on Tuesday, September 26th. Cantor Fitzgerald restated a “buy” rating and set a $49.00 price target on shares of Supernus Pharmaceuticals in a research note on Wednesday, September 27th. FBR & Co started coverage on Supernus Pharmaceuticals in a research note on Thursday, October 19th. They set a “buy” rating and a $53.00 price target on the stock. Cowen set a $50.00 price target on Supernus Pharmaceuticals and gave the company a “buy” rating in a research note on Monday, October 23rd. Finally, SunTrust Banks restated a “buy” rating and set a $61.00 price target on shares of Supernus Pharmaceuticals in a research note on Friday, November 3rd. Three analysts have rated the stock with a hold rating, eight have issued a buy rating and one has issued a strong buy rating to the stock. The company currently has an average rating of “Buy” and an average price target of $49.90.
TRADEMARK VIOLATION WARNING: This article was originally published by American Banking News and is the sole property of of American Banking News. If you are reading this article on another website, it was stolen and republished in violation of United States & international copyright law. The legal version of this article can be read at https://www.americanbankingnews.com/2018/01/22/supernus-pharmaceuticals-inc-supn-vp-sells-960800-00-in-stock.html.
Supernus Pharmaceuticals Company Profile
Supernus Pharmaceuticals, Inc is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. The Company offers Oxtellar XR (extended-release oxcarbazepine) and Trokendi XR (extended-release topiramate), its two treatments for patients with epilepsy.
Receive News & Ratings for Supernus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.